Identification
NameFerric pyrophosphate
Accession NumberDB09147
TypeSmall Molecule
GroupsApproved
Description

Ferric pyrophosphate, an iron replacement product, is a mixed-ligand iron complex in which iron (III) is bound to pyrophosphate and citrate.

Structure
Thumb
Synonyms
Iron pyrophosphate
Iron(III) pyrophosphate
External IDs Not Available
Product Ingredients
IngredientUNIICASInChI KeyDetails
Ferric pyrophosphate citrateUBY79OCO9G 1802359-96-1Not applicableDetails
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
TrifericSolution5.44 mg/mLParenteralRockwell Medical, Inc2015-02-06Not applicableUs
TrifericSolution272 mg/50mLHemodialysis; ParenteralRockwell Medical, Inc2015-09-04Not applicableUs
TrifericPowder272 mg/1ParenteralRockwell Medical, Inc2016-04-25Not applicableUs
TrifericPowder272 mg/272mgParenteralRopack Inc.2016-11-28Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNIIQK8899250F
CAS number10058-44-3
WeightAverage: 745.21
Monoisotopic: 745.475544666
Chemical FormulaFe4O21P6
InChI KeyCADNYOZXMIKYPR-UHFFFAOYSA-B
InChI
InChI=1S/4Fe.3H4O7P2/c;;;;3*1-8(2,3)7-9(4,5)6/h;;;;3*(H2,1,2,3)(H2,4,5,6)/q4*+3;;;/p-12
IUPAC Name
tetrairon(3+) ion tri(phosphonatooxy)phosphonate
SMILES
[Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O
Pharmacology
Indication

For the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (HDD- CKD).

Structured Indications
PharmacodynamicsNot Available
Mechanism of action

Iron delivered into the circulation binds to transferrin for transport to erythroid precursor cells to be incorporated into hemoglobin.

Related Articles
Absorption

The results of the present studies show that micronised, dispersible ferric pyrophosphate is as well absorbed as ferrous sulfate in adults. The absorption of iron depends upon the route of entry. The tissue that first clears parenterally administered iron from the bloodstream determines the bioavailability.

Volume of distribution

Exists in humans almost exclusively complexed to protein or in heme molecules.

Protein bindingNot Available
Metabolism

There is no destructive metabolism of iron because it takes place in a closed system.

Route of elimination

Very little iron is excreted. In normal, healthy adults, some daily loss of iron occurs through normal skin, hair, and nail loss, and GI losses.

Half life

1.48 hours

ClearanceNot Available
Toxicity

Ingestion of less than 40 mg/kg generally does not cause significant toxicity, although mild GI irritation may develop.Mild symptoms are likely to occur with peak iron concentrations greater than 300 mcg/dL, while peak concentrations of more than 500 mcg/dL generally causes severe symptoms.

Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AsenapineAsenapine can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium CarbonateCalcium carbonate can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CefdinirThe serum concentration of Cefdinir can be decreased when it is combined with Ferric pyrophosphate.Approved
ChlortetracyclineChlortetracycline can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
CimetidineCimetidine can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CinoxacinThe serum concentration of Cinoxacin can be decreased when it is combined with Ferric pyrophosphate.Approved, Withdrawn
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Ferric pyrophosphate.Approved, Investigational
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Ferric pyrophosphate.Approved
DemeclocyclineDemeclocycline can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DexlansoprazoleTAK-390MR can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DimercaprolDimercaprol may increase the nephrotoxic activities of Ferric pyrophosphate.Approved
Dipotassium phosphateFerric pyrophosphate can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Ferric pyrophosphate.Approved
DoxepinDoxepin can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DoxycyclineDoxycycline can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Ferric pyrophosphate.Approved
EnoxacinThe serum concentration of Enoxacin can be decreased when it is combined with Ferric pyrophosphate.Approved
EpinastineEpinastine can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EsomeprazoleEsomeprazole can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
FamotidineFamotidine can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FleroxacinThe serum concentration of Fleroxacin can be decreased when it is combined with Ferric pyrophosphate.Approved
FlumequineThe serum concentration of Flumequine can be decreased when it is combined with Ferric pyrophosphate.Withdrawn
GarenoxacinThe serum concentration of Garenoxacin can be decreased when it is combined with Ferric pyrophosphate.Investigational
GatifloxacinThe serum concentration of Gatifloxacin can be decreased when it is combined with Ferric pyrophosphate.Approved, Investigational
GemifloxacinThe serum concentration of Gemifloxacin can be decreased when it is combined with Ferric pyrophosphate.Approved, Investigational
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Ferric pyrophosphate.Withdrawn
LansoprazoleLansoprazole can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LevodopaThe serum concentration of Levodopa can be decreased when it is combined with Ferric pyrophosphate.Approved
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Ferric pyrophosphate.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Ferric pyrophosphate.Approved
Lipoic AcidFerric pyrophosphate can cause a decrease in the absorption of Lipoic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Nutraceutical
LomefloxacinThe serum concentration of Lomefloxacin can be decreased when it is combined with Ferric pyrophosphate.Approved
MagaldrateMagaldrate can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium HydroxideMagnesium hydroxide can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MethanthelineMethantheline can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MethyldopaThe serum concentration of Methyldopa can be decreased when it is combined with Ferric pyrophosphate.Approved
MetiamideMetiamide can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
MinocyclineMinocycline can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MoxifloxacinThe serum concentration of Moxifloxacin can be decreased when it is combined with Ferric pyrophosphate.Approved, Investigational
Nalidixic AcidThe serum concentration of Nalidixic Acid can be decreased when it is combined with Ferric pyrophosphate.Approved
NemonoxacinThe serum concentration of Nemonoxacin can be decreased when it is combined with Ferric pyrophosphate.Investigational
NizatidineNizatidine can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NorfloxacinThe serum concentration of Norfloxacin can be decreased when it is combined with Ferric pyrophosphate.Approved
OfloxacinThe serum concentration of Ofloxacin can be decreased when it is combined with Ferric pyrophosphate.Approved
OlanzapineOlanzapine can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
OmeprazoleOmeprazole can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
OxytetracyclineOxytetracycline can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PancrelipasePancrelipase can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PantoprazolePantoprazole can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PazufloxacinThe serum concentration of Pazufloxacin can be decreased when it is combined with Ferric pyrophosphate.Investigational
PefloxacinThe serum concentration of Pefloxacin can be decreased when it is combined with Ferric pyrophosphate.Approved
PenicillamineFerric pyrophosphate can cause a decrease in the absorption of Penicillamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PrulifloxacinThe serum concentration of Prulifloxacin can be decreased when it is combined with Ferric pyrophosphate.Investigational
RabeprazoleRabeprazole can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
RanitidineRanitidine can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RosoxacinThe serum concentration of Rosoxacin can be decreased when it is combined with Ferric pyrophosphate.Approved
Roxatidine acetateRoxatidine acetate can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium glycerophosphateFerric pyrophosphate can cause a decrease in the absorption of Sodium glycerophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium phosphateFerric pyrophosphate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Ferric pyrophosphate.Approved
TemafloxacinThe serum concentration of Temafloxacin can be decreased when it is combined with Ferric pyrophosphate.Withdrawn
TetracyclineTetracycline can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
TriethylenetetramineThe serum concentration of Ferric pyrophosphate can be decreased when it is combined with Triethylenetetramine.Approved
TrovafloxacinThe serum concentration of Trovafloxacin can be decreased when it is combined with Ferric pyrophosphate.Approved, Withdrawn
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Pubchem [Link]
  2. DRUGS.COM [Link]
  3. ChemIDplus [Link]
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (238 KB)
MSDSDownload (47 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedPreventionBacterial Infection Due to Helicobacter Pylori (H. Pylori) / Healthy Participants / Non-anemic Children1
1CompletedTreatmentEnd Stage Renal Disease (ESRD)2
1CompletedTreatmentIron-refractory, Iron-deficiency Anemia (IRIDA)1
1Not Yet RecruitingTreatmentAnemias / Chronic Kidney Disease (CKD) / Peritoneal dialysis therapy1
1, 2CompletedTreatmentEnd Stage Renal Disease (ESRD)1
2Not Yet RecruitingTreatmentIron-Refractory Iron-Deficiency Anemia1
4Not Yet RecruitingTreatmentAnemias / Bowel Diseases, Inflammatory1
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
PowderParenteral272 mg/1
PowderParenteral272 mg/272mg
SolutionHemodialysis; Parenteral272 mg/50mL
SolutionParenteral5.44 mg/mL
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6779468 No1996-12-312016-12-31Us
US7816404 No2009-04-172029-04-17Us
US6689275 No1996-12-312016-12-31Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
logP-1.4ChemAxon
pKa (Strongest Acidic)1.7ChemAxon
Physiological Charge-3ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area135.61 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity21.04 m3·mol-1ChemAxon
Polarizability9.03 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of inorganic compounds known as transition metal pyrophosphates. These are inorganic compounds in which the largest oxoanion is pyrophosphate, and in which the heaviest atom not in an oxoanion is a transition metal.
KingdomInorganic compounds
Super ClassMixed metal/non-metal compounds
ClassTransition metal oxoanionic compounds
Sub ClassTransition metal pyrophosphates
Direct ParentTransition metal pyrophosphates
Alternative ParentsInorganic salts / Inorganic oxides
SubstituentsTransition metal pyrophosphate / Inorganic oxide / Inorganic salt / Acyclic compound
Molecular FrameworkAcyclic compounds
External DescriptorsNot Available

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
oxidorectase activity
General Function:
Iron ion binding
Specific Function:
Stores iron in a soluble, non-toxic, readily available form. Important for iron homeostasis. Has ferroxidase activity. Iron is taken up in the ferrous form and deposited as ferric hydroxides after oxidation. Also plays a role in delivery of iron to cells. Mediates iron uptake in capsule cells of the developing kidney (By similarity).
Gene Name:
FTH1
Uniprot ID:
P02794
Uniprot Name:
Ferritin heavy chain
Molecular Weight:
21225.47 Da
References
  1. uniprot [Link]
Drug created on October 01, 2015 10:55 / Updated on September 01, 2017 12:02